Blood Clotting Articles & Analysis
36 news found
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). ...
Medical Equipment Pump Solutions Industry Overview IVD, which stands for in vitro diagnostics, refers to products that conduct testing on samples taken from the human body (such as blood, body fluids, and tissues) outside of the body in order to obtain clinical diagnostic information. ...
It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...
ByBayer AG
In AF, the upper chambers of the heart (atria) contract irregularly. As a result, blood does not flow properly, potentially allowing blood clots to form. These blood clots can break loose and travel to the brain, resulting in a stroke. ...
ByBayer AG
It seems like a simple device – a little basket shaped wire that can be put into a vein to remove a blood clot. But it is in fact a pioneering piece of equipment that could save thousands of lives. ...
The CHMP followed PRAC’s recommendation that JAK inhibitors should be used with caution in patients with risk factors for blood clots in the lungs and in deep veins (venous thromboembolism, VTE) other than those listed above. ...
Given the strong association of AF with increased risk of blood clot formation and hence, ischemic stroke in CKD patients, Biotricity proposes to combine the detection of this arrhythmia with other stroke risk factors of CKD patients (age, weight, height, BMI, CKD status, diabetes, heart disease) and ECG parameters to predict stroke risk in real-time. ...
In AF, the upper chambers (atria) of the heart contract irregularly.5 As a result, the atria do not empty completely, and blood does not flow properly, potentially allowing blood clots to form. These blood clots can break loose and travel to the brain, resulting in a stroke.6 About Stroke Stroke is the second ...
ByBayer AG
Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, which reduces blood supply to the brain, heart, kidneys and limbs causing strokes, heart attacks, kidney failure and limb amputations. ...
Hemophilia A is caused by a deficient production of the blood clotting factor VIII (FVIII) due to mutations in the F8 gene. Given as a single infusion directly into the bloodstream, ASC618 uses a modified and harmless AAV8 to deliver a shortened but optimized version of the F8 gene specifically to patients’ liver cells, the body’s main ...
Hemophilia A is caused by the lack of the blood clotting factor VIII (FVIII), a protein whose instructions are provided by F8, a gene that is mutated in people with the disease. ...
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for shockwave systems in the non-medical field, announced today the patent activity for the full year 2020 and the first quarter of ...
Led by a management team of industry veterans with substantial global experience in gene and cell therapy, ASC Therapeutics is developing multiple therapeutic programs based on four technology platforms: 1) In-vivo gene therapy of inherited blood clotting disorders, initially focusing on ASC618, a second generation gene replacement treatment for hemophilia A; 2) ...
Led by a management team of industry veterans with significant global experience in gene and cell therapy, ASC Therapeutics is developing multiple therapeutic programs based on four technology platforms: 1) In-vivo gene therapy of inherited blood clotting disorders, initially focusing on ASC618, a second generation gene replacement treatment for hemophilia A; 2) ...
ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells2. ...
Hemophilia A is caused by the lack of the blood clotting factor VIII (FVIII), a protein whose instructions are provided by F8, a gene that is mutated in people with the disease. ...
ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ...
” From Aidoc’s AI platform, Novant Health will be utilizing the intracranial hemorrhage (brain bleeds), pulmonary embolism (lung blood clots), incidental pulmonary embolism, c-spine fracture, and abdominal free air AI solutions. ...
ByAidoc
COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+ Adverse events were primarily mild, and no serious adverse events (SAEs) were noted Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up No cases of myocarditis or ...
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
ByBayer AG